RxDoctor Payments DataLook up a doctor →

Richard Hammond, DO

Neurology · Ogden, UTNPI 1174541742

Payments from drug & device makers

$708,688in general payments, 2019–2025

Across 2,075 payments — averaging $341.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$199K
  • Jazz Pharmaceuticals Inc.$181K
  • AbbVie$106K
  • Axsome Therapeutics, Inc.$104K
  • Sanofi$61K
  • Avadel CNS Pharmaceuticals, LLC$16K
  • plus $42K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.414$198,626
Jazz Pharmaceuticals Inc.300$181,265
AbbVie(2 entities)381$105,527
Axsome Therapeutics, Inc.125$103,642
Sanofi139$61,189
Avadel CNS Pharmaceuticals, LLC60$15,906
Harmony Biosciences LLC56$15,278
Johnson & Johnson21$13,761
Mallinckrodt Hospital Products Inc.2$1,896
Biogen70$1,848
Inspire Medical Systems, Inc.6$1,263
Novartis39$749
Genentech USA, Inc.43$727
Teva Pharmaceuticals USA, Inc.111$720
Bristol Myers Squibb31$632
Merz Pharmaceuticals, LLC13$363
UCB, Inc.14$362
Lundbeck LLC16$291
AstraZeneca(2 entities)15$289
SK Life Science, Inc.9$227
Acadia Pharmaceuticals Inc13$215
Takeda Pharmaceuticals U.S.A., Inc.7$194
TG Therapeutics, Inc.13$190
Argenx US, Inc.7$176
Boston Scientific5$176
Amneal Pharmaceuticals LLC9$175
Amgen(2 entities)8$173
E.r. Squibb & Sons, L.L.C.4$172
Vanda Pharmaceuticals Inc.7$127
Ipsen Biopharmaceuticals, Inc6$125
Arbor Pharmaceuticals, Inc.7$116
Pfizer5$110
ANI Pharmaceuticals, Inc.5$105
Octapharma USA, Inc.5$99
Neurelis, Inc.6$97
Eisai Inc.5$97
Sunovion Pharmaceuticals Inc.6$97
CSL Behring6$88
Lilly USA, LLC6$82
Neurocrine Biosciences, Inc.4$72
Supernus Pharmaceuticals, Inc.5$70
Banner Life Sciences, LLC3$69
Cala Health, Inc.3$66
Xeris Pharmaceuticals, Inc.3$61
Strongbridge US Inc.3$57
Endo Pharmaceuticals Inc.4$57
Greenwich Biosciences, Inc.3$56
Acorda Therapeutics, Inc2$52
GE HealthCare2$50
Biohaven Pharmaceuticals, Inc.2$49
MDD US Operations, LLC3$46
Adamas Pharmaceuticals, Inc.2$43
Cycle Pharmaceuticals Inc2$43
Impel Pharmaceuticals Inc.3$41
Philips North America LLC1$40
Merz North America, Inc.2$39
Otsuka America Pharmaceutical, Inc.2$36
Avanir Pharmaceuticals, Inc.2$35
3b Medical, Inc.2$35
Catalyst Pharmaceuticals, Inc.2$33

How this compares

$708,688 in reported general payments places this provider in the 90th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah →

Medicare billing

Part B allowed, 2024
$300,021
Medicare patients
909
Services billed
5,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Ogden

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →